Search results for " COLORECTAL CANCER"

showing 10 items of 120 documents

Detection of the DCC gene product in normal and malignant colorectal tissues and its relation to a codon 201 mutation.

1998

Protein expression of the putative tumour-suppressor gene DCC on chromosome 18q was evaluated in a panel of 16 matched colorectal cancer and normal colonic tissue samples together with DCC mRNA expression and allelic deletions (loss of heterozygosity, LOH). Determined by a polymerase chain reaction (PCR)-LOH assay, 12 of the 16 (75%) cases were informative with LOH occurring in 2 of the 12 cases. For DCC mRNA, transcripts could be detected in all analysed normal tissues (eight out of eight) by RT-PCR, whereas 6 of the 15 tumours were negative. DCC protein expression, investigated by immunohistochemistry using the monoclonal antibody 15041 A directed against the intracellular domain, was hom…

Cancer ResearchDeleted in Colorectal CancerDNA Mutational AnalysisLoss of HeterozygosityReceptors Cell SurfaceBiologymedicine.disease_causePolymerase Chain ReactionLoss of heterozygosityGene productmedicineHumansGenes Tumor SuppressorRNA MessengerRNA NeoplasmCodonGeneMessenger RNAMutationTumor Suppressor ProteinsfungiDCC ReceptorImmunohistochemistryNeoplasm ProteinsBlotting SouthernOncologyCancer researchImmunohistochemistryColorectal NeoplasmsCell Adhesion MoleculesImmunostainingResearch ArticleBritish Journal of Cancer
researchProduct

Novel insulin receptor substrate 1 and 2 variants in breast and colorectal cancer

2013

The insulin/insulin-like growth factor pathway is involved in breast and colorectal cancer (CRC) development. In the present study, we analyzed the coding region and short intron-exon borders of the insulin receptor substrate 1 and 2 (IRS‑1 and IRS‑2) genes in 12 cell lines derived from breast cancer (BC), 14 cell lines derived from CRC and 33 primary CRCs. The nucleotide variants identified in BC were 3 in IRS‑1, 1 of which (p.Arg267Cys) was novel and with a pathogenic potential as predicted by in silico analysis and 6 in IRS‑2. Twenty‑one variants in IRS‑1 and 18 in IRS‑2 were identified in the CRC samples. These included 11 novel IRS‑1 variants detected exclusively in CRCs, which include…

Cancer ResearchInsulin Receptor Substrate ProteinsSettore MED/06 - Oncologia MedicaIn silicoMutation MissenseBreast NeoplasmsColorectal NeoplasmBiologymedicine.disease_causeFrameshift mutationBreast cancerBreast cancerMCF-7 CellCell Line TumormedicineHumansMissense mutationFrameshift MutationInsulin Receptor Substrate ProteinSequence DeletionGeneticsMutationCaco-2 CellPolymorphism GeneticCancerGenetic VariationInsulin receptor substrate 1ArticlesGeneral MedicineInsulin receptor substrate 2HCT116 Cellsmedicine.diseaseColorectal cancerIRS1Mutagenesis InsertionalCell Transformation NeoplasticHT29 CellOncologyHCT116 CellBreast cancer; Colorectal cancer; Insulin receptor substrate 1; Insulin receptor substrate 2; Breast Neoplasms; Caco-2 Cells; Cell Line Tumor; Cell Transformation Neoplastic; Colorectal Neoplasms; Female; Frameshift Mutation; Genetic Variation; HCT116 Cells; HT29 Cells; Humans; Insulin Receptor Substrate Proteins; MCF-7 Cells; Mutagenesis Insertional; Mutation Missense; Polymorphism Genetic; Sequence Deletion; Signal Transduction; Cancer Research; OncologyInsulin Receptor Substrate ProteinsMCF-7 CellsFemaleCaco-2 CellsColorectal NeoplasmsHT29 CellsBreast NeoplasmHumanSignal Transduction
researchProduct

Tumor and its microenvironment: a synergistic interplay.

2013

The mutual and interdependent interaction between tumor and its microenvironment is a crucial topic in cancer research. Recently, it was reported that targeting stromal events could improve efficacies of current therapeutics and prevent metastatic spreading. Tumor microenvironment is a "complex network" of different cell types, soluble factors, signaling molecules and extracellular matrix components, which orchestrate the fate of tumor progression. As by definition, cancer stem cells (CSCs) are proposed to be the unique cell type able to maintain tumor mass and survive outside the primary tumor at metastatic sites. Being exposed to environmental stressors, including reactive oxygen species …

Cancer ResearchStromal cellEpithelial-Mesenchymal TransitionAngiogenesisCell SurvivalBiologyCancer stem cellCell MovementNeoplasmsmedicineTumor MicroenvironmentAnimalsHumansEpithelial–mesenchymal transitionNeoplasm MetastasisStem Cell NicheHypoxiaTumor microenvironmentNeovascularization Pathologicmedicine.diseaseAngiogenesis CAFs CAMs CRC CSCs ECM EMT GSH HIF Hypoxia MMPs ROS Tumor microenvironment VEGF cancer stem cells cancer-associated fibroblasts cancer-associated macrophages colorectal cancer epithelial mesenchymal transition extracellular matrix hypoxia-inducible factor matrix metalloproteinase reactive oxygen species reduced glutathione vascular endothelial growth factorPrimary tumorTumor progressionImmunologyCancer researchNeoplastic Stem CellsCancer-Associated FibroblastsOxidation-ReductionSignal Transduction
researchProduct

Colon Cancer Stem Cells: Bench-to-Bedside—New Therapeutical Approaches in Clinical Oncology for Disease Breakdown

2011

It is widely accepted by the scientific community that cancer, including colon cancer, is a “stem cell disease”. Until a few years ago, common opinion was that all neoplastic cells within a tumor contained tumorigenic growth capacity, but recent evidences hint to the possibility that such a feature is confined to a small subset of cancer-initiating cells, also called cancer stem cells (CSCs). Thus, malignant tumors are organized in a hierarchical fashion in which CSCs give rise to more differentiated tumor cells. CSCs possess high levels of ATP-binding cassette (ABC) transporters and anti-apoptotic molecules, active DNA-repair, slow replication capacities and they produce growth factors tha…

Cancer Researchcancer stem cellColorectal cancerCellPopulationDiseaseReviewBioinformaticslcsh:RC254-282colorectal cancer (CRC)Cancer stem cellMedicineCD133educationeducation.field_of_studycancer stem cell; colorectal cancer (CRC); CD133; differentiationbusiness.industryCancerdifferentiationlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasemedicine.anatomical_structureOncologyCancer cellCancer researchStem cellbusiness
researchProduct

Hsp60 molecular anatomy and role in colorectal cancer diagnosis and treatment

2011

Quantitative changes in Hsp60 during the development of some tumors suggest that this chaperonin plays a role in carcinogenesis. A description of the specific role(s) of Hsp60 in tumor-cell growth and proliferation is still incomplete, but it is already evident that monitoring its levels and distribution in tissues and fluids has potential for diagnosis and staging, and for assessing prognosis and response to treatment. Although Hsp60 is considered an intramitochondrial protein, it has been demonstrated in the cytosol, cell membrane, vesicles, cell surface, extracellular space, and blood. The knowledge that Hsp60 occurs at all these locations opens new avenues for basic and applied research…

Clinical OncologyOncologymedicine.medical_specialtyGeneral Immunology and Microbiologybusiness.industryColorectal cancerCellChaperonin 60medicine.disease_causeBioinformaticsmedicine.diseaseResponse to treatmentGeneral Biochemistry Genetics and Molecular BiologyChaperoninmedicine.anatomical_structureInternal medicineBiomarkers TumorHumansMedicineHSP60Chaperoning system Chaperonology Chaperonopathies Chaperonotherapy Hsp60 Clinical oncology Colorectal cancer ReviewColorectal NeoplasmsbusinessCarcinogenesisFrontiers in Bioscience
researchProduct

Characteristics of the colorectal cancers diagnosed in the early 2000s in Italy. Figures from the IMPATTO study on colorectal cancer screening

2015

The impact of organized screening programmes on colorectal cancer (CRC) can be observed at a population level only several years after the implementation of screening. We compared CRC characteristics by diagnostic modality (screen-detected, non-screen-detected) as an early outcome to monitor screening programme effectiveness. Data on CRCs diagnosed in Italy from 2000 to 2008 were collected by several cancer registries. Linkage with screening datasets made it possible to divide the cases by geographic area, implementation of screening, and modality of diagnosis (screen-detected, non-screen-detected).We compared the main characteristics of the different subgroups of CRCs through multivariate …

Colorectal cancer; Colorectal cancer screening; Italy; Epidemiology; Public Health Environmental and Occupational HealthItalyEpidemiologyPublic Health Environmental and Occupational HealthSettore MED/42 - Igiene Generale E ApplicataColorectal cancerColorectal cancer screening
researchProduct

Colorectal cancer defeating? Challenge accepted!

2013

Colorectal tumours are actually considered as aberrant organs, within it is possible to notice a different stage of cell growth and differentiation. Their origin is reported to arise from a subpopulation of tumour cells endowed with, just like the healthy stem cells, self-renewal and aberrant multi-lineage differentiation capacity likely to be called colorectal cancer stem cells (CCSCs). Cancer stem cells (CSCs) fate, since their origin, reflects the influences from their microenvironment (or niche) both in the maintenance of stemness, in promoting their differentiation, and in inducing epithelial-mesenchymal transition, responsible of CSCs dissemination and subsequent formation of metastat…

Epithelial-Mesenchymal TransitionColorectal cancerClinical BiochemistryBiologyBiochemistryImmune systemCancer stem cellmedicineTumor MicroenvironmentAnimalsHumansMolecular Targeted TherapyCytotoxicityMolecular BiologyCell growthChemotaxisGeneral MedicineCell cyclemedicine.diseaseGene Expression Regulation NeoplasticDrug Resistance NeoplasmCancer stem cell Colorectal cancer Immune system Individualized therapy Targeting Tumour microenvironment.ImmunologyCancer researchNeoplastic Stem CellsMolecular MedicineStem cellColorectal NeoplasmsSignal TransductionMolecular aspects of medicine
researchProduct

A New Comorbidity in Periodontitis: Fusobacterium nucleatum and Colorectal Cancer

2022

There is very recent and strong evidence relating Fusobacterium nucleatum to colorectal cancer. In this narrative review, we update the knowledge about gingival dysbiosis and the characteristics of Fusobacterium nucleatum as one of the main bacteria related to periodontitis. We provide data on microbiome, epidemiology, risk factors, prognosis, and treatment of colorectal cancer, one of the most frequent tumours diagnosed and whose incidence increases every year. We describe, from its recent origin, the relationship between this bacterium and this type of cancer and the knowledge and emerging mechanisms that scientific evidence reveals in an updated way. A diagram provided synthesizes the pa…

Fusobacterium nucleatum colorectal cancer dysbiosis periodontitisstomatognathic diseasesstomatognathic systemFusobacterium nucleatumDysbiosisGeneral MedicinePeriodontitisColorectal cancer
researchProduct

Blefaritis asociada al tratamiento con Cetuximab en adenocarcinoma colorrectal avanzado

2008

espanolCaso clinico: Mujer de 52 anos diagnosticada de adenocarcinoma colorrectal, remitida a nuestro servicio por presentar tras iniciar tratamiento con Cetuximab reaccion adversa palpebral. Discusion: El Cetuximab es un anticuerpo monoclonal cuya diana es el receptor del factor de crecimiento epidermico. Ha sido incorporado recientemente al tratamiento de tumores, principalmente el cancer colorrectal metastatico y los tumores del area otorrinolaringologica. Su tolerancia es en principio mejor que la de los agentes quimioterapicos clasicos. Sin embargo, no esta exento de efectos secundarios. La toxicidad palpebral asociada a Cetuximab ha sido recientemente descrita, por lo que la patogenia…

Gynecologymedicine.medical_specialtyEpidermal growth factor receptor activityCetuximabbusiness.industryreceptor del factor de crecimiento epidérmicoCancermedicine.diseasedigestive system diseasesSurgeryAdvanced colorectal cancerOphthalmologyblefaritisMedicineAdenocarcinomaanticuerpos monoclonalesbusinessneoplasmsAdenocarcinoma colorrectalmedicine.drugArchivos de la Sociedad Española de Oftalmología
researchProduct

Codon 12 and codon 13 mutations in K-RAS differentially affect colorectal carcinoma cells

2014

K-RAS colorectal cancer
researchProduct